Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(9):671-678; doi:10.1093/jnci/80.9.671
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rowinsky, E. K.
Right arrow Articles by Donehower, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowinsky, E. K.
Right arrow Articles by Donehower, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 9, 671-678, July 6, 1988
© 1988 Oxford University Press

Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity2

Eric K. Rowinsky, Dennis A. Noe, Douglas W. Orr, Louise B. Grochow, David S. Ettinger, Ross C. Donehower3,4

3The Johns Hopkins Oncology Center 600 North Wolfe St., Baltimore, Maryland 21205

N-Methylformamide (NMF) has been an agent of considerable interest to oncologists because of its broad spectrum of preclinical antitumor activity, tumor-differentiating abilities, and radiosensitizing and chemosensitizing properties. In this report, the pharmacokinetics of NMF are described, based on data from two phase I studies exploring both iv and oral routes of administration. Mean peak NMF plasma concentrations at recommended phase II doses were 0.46 mmol/L for NMF administered orally, 600 mg/m2 three times/week x 4 weeks every 6 weeks, and 2.78 mmol/L for NMF administered as a weekly iv bolus at 2, 000 mg/m2 x 3 weeks every 4 weeks. These NMF concentrations were significantly lower than the concentrations that have been demonstrated to induce antineoplastic and relevant biologic effects in preclinical studies. Plasma disappearance curves were biphasic in the majority of patients; however, 25% of the curves were best fit by a monoexponential kinetic model. Mean alpha half-life and beta half-life values (± SE) were 10 ± 2 and 732 ± 93 min, respectively. Volumes of distribution for the theoretical central compartment (Vc) and at steady-state (Vss) were 13.8 ± 1.1 L/m2 and 18.7 ± 1.1 L/m2, respectively. The mean plasma clearance of NMF was 19.1 ± 2.1 mL/min per square meter, and the relative contributions to parent compound disposition by respiratory and renal routes were insignificant. No metabolites were identified. Gastrointestinal absorption of oral NMF was rapid and nearly complete; oral bioavailability was calculated to be 0.87. Pharmacodynamic associations were observed between the magnitude of the area under the plasma disappearance curves and hepatotoxicity, the dose-limiting toxic effect of iv NMF, and the symptom complex of nausea, vomiting, and malaise, which precluded dose escalation of oral NMF. [J Natl Cancer Inst 1988; 80: 671–678]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.